Ronster schreef op 10 mei 2021 15:25:
[...]Gelukkig denkt Novacyt daar anders over. Ik ga er ook vanuit dat zij iets (haha) meer marktkennis hebben en om die reden een betere inschatting kunnen maken van de potentie dan dat jij dat kan. Uit het persbericht van 23 april:
PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection
of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a
result in approximately 15 minutes. Novacyt has been working with a partner to develop
this test, which is able to detect the virus regardless of current known mutations. The
Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it
to complement Novacyt’s established position in COVID-19 PCR testing. As the market for
COVID-19 testing continues to develop,
the Directors believe this product could add
significant revenues for Novacyt.